Company Focus
Novartis
Latest Novartis News
Pharmaceutical
A US district court judge has found that the Department of Health and Human Services (HHS) must preapprove the use of 340B rebate models before they can be implemented. 19 May 2025
Related News
Insights
Company Spotlight
An American biotech company developing solutions that treat urothelial and specialty cancers.
Latest News & Features of interest to Novartis
Biotechnology
Last week saw Novavax receive full approval from the US Food and Drug Administration (FDA) for its COVID-19 vaccine, but with post-market requirements. Swiss gene-editing company CRISPR Therapeutics linked up with Sirius Therapeutics to develop siRNA therapeutics, notably the latter’s SRSD107 in cardiovascular indications. The FDA last week announced a new executive order aiming to provide a pathway for prescription drugs from Canada, Also of note, Gilead Sciences released positive results for its Trodelvy ASCENT-03 study in metastatic triple negative breast cancer (mTNBC). 25 May 2025
Pharmaceutical
US antivirals major Gilead Sciences yesterday released positive top-line results from the Phase III ASCENT-03 study of Trodelvy (sacituzumab govitecan-hziy). 24 May 2025
Biotechnology
US biotech Ionis Pharmaceuticals has reported positive top-line data from the Phase III ESSENCE trial of its antisense drug olezarsen in patients with moderate hypertriglyceridemia who are at risk of atherosclerotic cardiovascular disease. 23 May 2025
Pharmaceutical
Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering its efforts to broaden use of its dual-drug regimen, Avmapki Fakzynja Co-Pack, beyond its recently approved indication in a rare form of ovarian cancer. 23 May 2025
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its May 2025 meeting. Final approvals from the European Commission are now expected in the third quarter of this year. 23 May 2025
Pharmaceutical
The UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that Filspari (sparsentan) can be used in the National Health Service (NHS) in England as an option to treat primary IgA nephropathy in adults with a urine protein excretion of 1.0g/day or more, or a urine protein-to-creatinine ratio of 0.75g/g or more. 23 May 2025
Pharmaceutical
Japanese drugmaker Astellas and US pharma giant Pfizer have announced longer-term follow-up results from an open-label extension of the Phase III ARCHES study. 23 May 2025
Pharmaceutical
Privately-held French drugmaker Servier and China-based BioNova Pharmaceuticals today announce that they have entered into a definitive agreement under which Servier will acquire BN104, a potential best-in-class menin inhibitor currently in Phase I/II development for the treatment of acute leukemias. 23 May 2025
Biotechnology
Among the companies displaying the strength of Chinese research in oncology at the 2025 ASCO Annual Meeting will be Hutchmed. 23 May 2025
Pharmaceutical
The oncology community’s biggest gathering returns to Chicago from May 30 to June 3, and all signs suggest the 2025 ASCO Annual Meeting will be a watershed moment. 23 May 2025
Latest In Brief for Novartis
Biosimilars
At its May meeting, the European Medicines Agency’s (EMA) human medicines committee (CHMP) adopted positive opinions for three biosimilar medicines: 23 May 2025
Latest Ones To Watch News
US clinical-stage biotech Vigil Neuroscience saw its share price skyrocket more than 240% to $7.89 pre-market, on the news that French pharma major Sanofi had made a takeover bid for the company. 22 May 2025
30 April 2025
28 April 2025
Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze